EVIDENCE MAP
Will I get the study’s result?
Read who took part and what was compared before holding on to a number.
Keep the comparison in view
A placebo is a dummy treatment used as a comparison.
The summaries below describe trial groups. They do not forecast a result for one person.
Semaglutide: the STEP 1 trial
The STEP 1 study tested semaglutide in adults without diabetes. To join, people had to meet weight requirements and, in some cases, have a related health problem.
By week 68, the semaglutide group had lost 14.9% of body weight on average, compared with 2.4% for the dummy-treatment group.
People in both study groups had regular visits and got advice on daily habits, such as eating and exercise.
READ WITH THE RESULT
This gives a group average under trial conditions. The drug’s maker funded the study, and personal results varied.
Read the published study ↗Tirzepatide: the SURMOUNT-1 trial
Adults in the tirzepatide SURMOUNT-1 study had no diabetes. They qualified based on weight, with a related health problem required in some cases.
The study compared groups taking different amounts of tirzepatide.
At week 72, average weight loss was 15.0% in the group taking the lowest amount. It was 19.5% in the middle group and 20.9% in the group taking the highest amount. The dummy-treatment group lost 3.1% on average.
People in every study group had regular visits and got advice on daily habits, such as eating and exercise.
READ WITH THE RESULT
The drug’s maker funded this study. Each medicine group took a different amount. These study amounts are not instructions for your treatment.
Read the published study ↗Liraglutide: the SCALE trial
The liraglutide SCALE study left out adults who had type 2 diabetes. This condition affects blood sugar.
People had to meet the study’s weight requirements to join. Some also needed high blood pressure or abnormal levels of fat, such as cholesterol, in their blood.
The study measured weight in kilograms, a unit of weight like pounds. The pound amounts below give the same results.
Over 56 weeks, average weight loss was 8.4 kilograms (about 18.5 pounds) with liraglutide. It was 2.8 kilograms (about 6.2 pounds) with a dummy treatment.
The earlier studies give loss as a percentage of starting weight. This study gives the amount of weight lost.
READ WITH THE RESULT
Read who could join with the result. This study’s people and length differ from the other studies on this page.
Read the published study ↗
Ask about the plan for stopping
A STEP 1 follow-up found that participants gained back about two-thirds of their lost weight over the year after they stopped semaglutide.
That follow-up had a smaller group than the main trial.
Ask the person treating you what the plan will be if you stop the medicine.
Read the follow-up study ↗